SMTI

Company Overview — What Does Sanara MedTech Inc. Do?

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical Activated Collagen Adjuvant powder that helps in the natural wound healing process; Biako¯s Antimicrobial Skin & Wound Cleanser, a patented wound cleansing spray that disrupts extracellular polymeric substances to eradicate biofilm; and Biako¯s Antimicrobial Skin & Wound Irrigation Solution that works to irrigate and remove microbes from the wound bed to help eliminate planktonic, immature, and mature biofilms. It also provides Biako¯s Antimicrobial Wound Gel, a patented gel that synergistically disrupts extracellular polymeric substances to help eliminate biofilm microbes in the gel to help in wound healing; HYCOL Hydrolyzed Collagen, an additive free Type I bovine collagen that offers hydrolyzed collagen fragments to the wound bed that are a fraction of the size of native collagen; and PULSAR II Advanced Wound Irrigation Debridement System, a portable and no touch hydro-mechanical debridement system that removes bacteria and necrotic tissue without disrupting healthy tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. Sanara MedTech Inc. (SMTI) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Zachary B. Fleming and employs approximately 60 people. With a market capitalization of $158M, SMTI is one of the notable companies in the Healthcare sector.

Sanara MedTech Inc. (SMTI) Stock Rating — Reduce (April 2026)

As of April 2026, Sanara MedTech Inc. receives a Reduce rating with a composite score of 37.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SMTI ranks #3,237 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Sanara MedTech Inc. ranks #489 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SMTI Stock Price and 52-Week Range

Sanara MedTech Inc. (SMTI) currently trades at $17.01. The stock gained $0.04 (0.2%) in the most recent trading session. The 52-week high for SMTI is $35.95, which means the stock is currently trading -52.7% from its annual peak. The 52-week low is $18.29, putting the stock -7.0% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is SMTI Overvalued or Undervalued? — Valuation Analysis

Sanara MedTech Inc. (SMTI) carries a value factor score of 49/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The price-to-book ratio stands at 26.02x, versus the sector average of 2.75x. The price-to-sales ratio is 1.59x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, SMTI trades at 68.28x EV/EBITDA, versus 6.34x for the sector.

Overall, SMTI's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Sanara MedTech Inc. Profitability — ROE, Margins, and Quality Score

Sanara MedTech Inc. (SMTI) earns a quality factor score of 46/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -655.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -53.3% versus the sector average of -33.1%.

On a margin basis, Sanara MedTech Inc. reports gross margins of 92.1%, compared to 71.5% for the sector. The operating margin is -1.7% (sector: -66.1%). Net profit margin stands at -37.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 30.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SMTI Debt, Balance Sheet, and Financial Health

Sanara MedTech Inc. has a debt-to-equity ratio of 775.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.80x, suggesting adequate working capital coverage. Total debt on the balance sheet is $46M. Cash and equivalents stand at $15M.

SMTI has a beta of 1.01, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Sanara MedTech Inc. is 40/100, reflecting average volatility within the normal range for its sector.

Sanara MedTech Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Sanara MedTech Inc. reported revenue of $97M and earnings per share (EPS) of $-4.36. Net income for the quarter was $-39M. Gross margin was 92.1%. Operating income came in at $-1M.

In FY 2025, Sanara MedTech Inc. reported revenue of $103M and earnings per share (EPS) of $-4.36. Net income for the quarter was $-38M. Gross margin was 92.7%. Revenue grew 19.0% year-over-year compared to FY 2024. Operating income came in at $7M.

In Q3 2025, Sanara MedTech Inc. reported revenue of $26M and earnings per share (EPS) of $-3.52. Net income for the quarter was $-30M. Gross margin was 92.9%. Revenue grew 21.5% year-over-year compared to Q3 2024. Operating income came in at $3M.

In Q2 2025, Sanara MedTech Inc. reported revenue of $26M and earnings per share (EPS) of $-0.23. Net income for the quarter was $-2M. Gross margin was 92.5%. Revenue grew 28.1% year-over-year compared to Q2 2024. Operating income came in at $-31,348.

Over the past 8 quarters, Sanara MedTech Inc. has demonstrated a growth trajectory, with revenue expanding from $20M to $97M. Investors analyzing SMTI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SMTI Dividend Yield and Income Analysis

Sanara MedTech Inc. (SMTI) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SMTI Momentum and Technical Analysis Profile

Sanara MedTech Inc. (SMTI) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 57/100 reflects moderate short selling activity.

SMTI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Sanara MedTech Inc. (SMTI) ranks #489 out of 838 stocks based on the Blank Capital composite score. This places SMTI in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SMTI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SMTI vs S&P 500 (SPY) comparison to assess how Sanara MedTech Inc. stacks up against the broader market across all factor dimensions.

SMTI Next Earnings Date

No upcoming earnings date has been announced for Sanara MedTech Inc. (SMTI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SMTI? — Investment Thesis Summary

The quantitative profile for Sanara MedTech Inc. suggests caution. Momentum is weak at 17/100, a headwind for near-term performance.

In summary, Sanara MedTech Inc. (SMTI) earns a Reduce rating with a composite score of 37.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SMTI stock.

Related Resources for SMTI Investors

Explore more research and tools: SMTI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SMTI head-to-head with peers: SMTI vs AZN, SMTI vs SLGL, SMTI vs VMD.